Quel est le prix pour Metagenomi, Inc. Common Stock (MGX)

Le prix pour Metagenomi, Inc. Common Stock (MGX) est $1.21

Quelle est la capitalisation boursière pour Metagenomi, Inc. Common Stock (MGX)

La capitalisation boursière pour Metagenomi, Inc. Common Stock (MGX) est $45.55M

Revenus de Metagenomi, Inc. Common Stock (MGX)

Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.

Année	Revenus	Changez
Pas assez de données pour les dates fournies.

Année

Revenus

Changez

Pas assez de données pour les dates fournies.

Entreprise	Revenus	Différence de revenus	Pays
Vertex Pharmaceuticals Incorporated VRTX.US	$12.62B	-	US
Argenx SE ARGX.US	$6.02B	-	NL
CSL Limited CSL.AX	$15.70B	-	AU
Lonza Group AG LONN.SW	-	-	CH
Moderna, Inc. MRNA.US	$2.23B	-	US

Entreprise

Revenus

Différence de revenus

Pays